The Network for Drug Discovery & Development Berlin-Brandenburg was officially launched on January 16th 2007 as an open interdisciplinary initiative with the aim to accelerate the transfer of clinical relevant findings into innovative drugs and therapeutic concepts. The network, which was co-founded by the Leibniz Institut für Molekulare Pharmakologie (FMP) and the competence network biotechnology, BioTOP Berlin-Brandenburg, offers state-of-the-art technology and expertise in the field of drug discovery. It guides researchers through the highly complex process from target discovery to the point of preclinical development of drug candidates and helps locating resources needed in each phase. This ranges from the initial high throughput/high content screening (HTS/HCS) during the assay development phase to the development of a drug candidate. The latter is usually sponsored by the pharmaceutical industry due to the significant commitment in terms of costs, resources, and time.
